roll_call_votes: 119, senate, 2, 103
Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API
This data as json
| congress | chamber | session | roll_call_number | date | question | vote_type | description | result | bill_id | legislation_type | legislation_number | yea_count | nay_count | present_count | not_voting_count | source_url |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 119 | senate | 2 | 103 | 2026-04-23 | On the Amendment S.Amdt. 5336 to S.Con.Res. 33 (No short title on file) | Wyden Amdt. No. 5336 -- To establish a deficit-neutral reserve fund relating to requiring the Comptroller General of the United States to conduct a study related to economic consequences of private or confidential drug pricing agreements struck by any Federal department, agency, or office with any pharmaceutical manufacturer. | Amendment Rejected | 48 | 50 | 0 | 2 | https://www.senate.gov/legislative/LIS/roll_call_votes/vote1192/vote_119_2_00103.xml |